3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
6
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
152
Neoplasms
108
Carcinoma, Non-Small-Cell Lung
83
Colorectal Neoplasms
81
Prostatic Neoplasms
80
Lung Neoplasms
71
Leukemia, Myeloid, Acute
48
Carcinoma, Hepatocellular
48
Pancreatic Neoplasms
45
Neoplasm Metastasis
39
Multiple Myeloma
37
Recurrence
34
Triple Negative Breast Neoplasms
29
Squamous Cell Carcinoma of Head and Neck
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Melanoma
27
Glioblastoma
27
Head and Neck Neoplasms
25
Brain Neoplasms
25
Uterine Cervical Neoplasms
24
Stomach Neoplasms
24
Rectal Neoplasms
24
Ovarian Neoplasms
24
Small Cell Lung Carcinoma
22
Carcinoma, Renal Cell
20
Lymphoma, B-Cell
19
Lymphoma, Follicular
18
Lymphoma
18
Endometrial Neoplasms
18
Glioma
17
Interventions
belantamab mafodotin
1
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Amyloidosis
×
90 days
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled